USA flag logo/image

An Official Website of the United States Government

A Novel Apoptosis Assay with Antibodies to ssDNA

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
55612
Program Year/Program:
2001 / STTR
Agency Tracking Number:
2R42CA083508-03
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
APOSTAIN, INC.
8877 COLLINS AVE, STE 1009 MIAMI, FL 33154 MIAMI, FL 33154
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: A Novel Apoptosis Assay with Antibodies to ssDNA
Agency: HHS
Contract: PHS2001-2
Award Amount: $0.00
 

Abstract:

DESCRIPTION (Provided by Applicant): Work performed during the Phase I of this project has demonstrated that formamide induces selective denaturation of DNA in apoptotic cells. This novel effect of formamide on the stability of apoptotic DNA combined with the detection of denatured DNA with monoclonal antibody (MAb)against single-stranded DNA, has made it possible to develop a sensitive and specific assay for the identification of apoptosis. The major goal of the proposed Phase II project is to develop our formamide-MAb assay for possible commercial applications. For this purpose, we will develop assay protocols for staining of histological sections from formalin-fixed paraffin-embedded archival material, frozen tissue sections and cytological preparations. Production of a formamide-MAb assay kit for commercial use will be the major goal of the Phase II project. Work proposed for the development of the kit will involve production and conjugation of anti-ssDNA MAb, selection of optimal protocols and reagents for the kit and evaluation of the stability of the kit components under variable storage and shipping conditions. To develop applications of formamide-MAb assay for the evaluation and prediction of therapeutic response in solid tumors, we propose to: a) evaluate relation between chemosensitivity and the induction of apoptosis, b) measure apoptosis in endothelium of tumors treated with antiangiogenesis factors and c) study apoptosis in tumors treated with specific apoptosis-inducing therapy (e.g. death ligand TRAIL). High-throughput ELISA based on formamide-MAb technique will be developed as a new and rapid method for high-volume screening of drugs for their apoptotic and anti-apoptotic activity. PROPOSED COMMERCIAL APPLICATION: Significant commercial applications could be expected for the proposed assay, which provides sensitive, specific and universal detection of apoptosis in cells and tissue sections and makes possible high-throughput screening of drugs for apoptotic and anti-apoptotic activity.

Principal Investigator:

Oskar S. Frankfurt
3058683998
APOSTAIN@BELLSOUTH.NET

Business Contact:

Oskar frankfurt
3058683998
APOSTAIN@BELLSOUTH.NET
Small Business Information at Submission:

APOSTAIN, INC.
8877 COLLINS AVE, STE 1009 MIAMI, FL 33154 MIAMI, FL 33154

EIN/Tax ID: 650759282
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF MIAMI
UNIVERSITY OF MIAMI
MIAMI, FL 32888
RI Type: Nonprofit college or university